Patents by Inventor Padmini Kavuru
Padmini Kavuru has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11535644Abstract: The invention relates to a crystalline methanol or dimethyl sulfoxide solvated form of regadenoson and an anhydrous polymorph of regadenoson. The invention is also directed to the preparation of the methanol or dimethyl sulfoxide solvated and anhydrous solid-state forms of regadenoson. In particular, the invention relates to the preparation of the anhydrous polymorph of regadenoson in a stable form from the dimethyl sulfoxide solvated form of regadenoson, which preparation is purifiable and scalable.Type: GrantFiled: September 28, 2020Date of Patent: December 27, 2022Assignee: Macfarlan Smith LimitedInventor: Padmini Kavuru
-
Patent number: 11524953Abstract: The present disclosure relates to a stabilized anhydrous p-toluenesulfonic acid salt of niraparib, Form A. The present disclosure is also related to processes for the preparation of the stabilized anhydrous p-toluenesulfonic acid salt of niraparib. Further, the present disclosure also relates to pharmaceutical compositions comprising the stabilized anhydrous p-toluenesulfonic acid salt of niraparib and methods for treating disease using the stabilized anhydrous p-toluenesulfonic acid salt of niraparib.Type: GrantFiled: April 5, 2021Date of Patent: December 13, 2022Assignee: Macfarlan Smith LimitedInventor: Padmini Kavuru
-
Patent number: 11440908Abstract: The present disclosure relates to a dasatinib co-crystal form comprising dasatinib and a second compound, also referred to as a co-crystal former, wherein the second compound is selected from butyl paraben, propyl paraben and ethyl vanillin. The present disclosure is also related to an ethyl formate solvate form of dasatinib. The present disclosure is also related to processes for the preparation of the dasatinib co-crystal and solvate forms of dasatinib. Further, the present disclosure also relates to pharmaceutical compositions comprising the dasatinib co-crystal and solvate forms of dasatinib and methods for treating disease using the dasatinib co-crystal and solvate forms of dasatinib.Type: GrantFiled: October 22, 2020Date of Patent: September 13, 2022Assignee: Johnson Matthey Public Limited CompanyInventor: Padmini Kavuru
-
Publication number: 20210221787Abstract: The present disclosure relates to a stabilized anhydrous p-toluenesulfonic acid salt of niraparib, Form A. The present disclosure is also related to processes for the preparation of the stabilized anhydrous p-toluenesulfonic acid salt of niraparib. Further, the present disclosure also relates to pharmaceutical compositions comprising the stabilized anhydrous p-toluenesulfonic acid salt of niraparib and methods for treating disease using the stabilized anhydrous p-toluenesulfonic acid salt of niraparib.Type: ApplicationFiled: April 5, 2021Publication date: July 22, 2021Inventor: Padmini KAVURU
-
Publication number: 20210032235Abstract: The present disclosure relates to a dasatinib co-crystal form comprising dasatinib and a second compound, also referred to as a co-crystal former, wherein the second compound is selected from butyl paraben, propyl paraben and ethyl vanillin. The present disclosure is also related to an ethyl formate solvate form of dasatinib. The present disclosure is also related to processes for the preparation of the dasatinib co-crystal and solvate forms of dasatinib. Further, the present disclosure also relates to pharmaceutical compositions comprising the dasatinib co-crystal and solvate forms of dasatinib and methods for treating disease using the dasatinib co-crystal and solvate forms of dasatinib.Type: ApplicationFiled: October 22, 2020Publication date: February 4, 2021Inventor: Padmini KAVURU
-
Publication number: 20210009626Abstract: The invention relates to a crystalline methanol or dimethyl sulfoxide solvated form of regadenoson and an anhydrous polymorph of regadenoson. The invention is also directed to the preparation of the methanol or dimethyl sulfoxide solvated and anhydrous solid-state forms of regadenoson. In particular, the invention relates to the preparation of the anhydrous polymorph of regadenoson in a stable form from the dimethyl sulfoxide solvated form of regadenoson, which preparation is purifiable and scalable.Type: ApplicationFiled: September 28, 2020Publication date: January 14, 2021Inventor: Padmini KAVURU
-
Patent number: 10842797Abstract: Co-crystals comprising at least one nutraceutical compound and at least one co-crystal former with or without impurities. These co-crystals may be included in compositions (optionally also including other components such as pharmaceutically acceptable excipients, other nutritional supplements, etc.) having utility as pharmaceuticals, nutraceuticals, nutritional supplements, and foodstuffs.Type: GrantFiled: May 24, 2019Date of Patent: November 24, 2020Assignee: UNIVERSITY OF SOUTH FLORIDAInventors: Michael John Zaworotko, Heather Clarke, Arora Kapildev, Padmini Kavuru, Roland Douglas Shytle, Twarita Pujari, Lissette Marshall, Tien Teng Ong
-
Patent number: 10730836Abstract: The present disclosure is directed to novel forms of apremilast and pharmaceutical compositions comprising any of the novel forms of apremilast. Also provided are processes for the preparation of novel forms of apremilast.Type: GrantFiled: August 29, 2019Date of Patent: August 4, 2020Assignee: Johnson Matthey Public Limited CompanyInventor: Padmini Kavuru
-
Publication number: 20200138759Abstract: The present invention relates to new pharmaceutical salts of ?-GPA which exhibit improved physical properties. In particular, the invention relates to salts of ?-GPA with improved flow properties (e.g., improved Carr's index and/or Hausner ratio) such as fumarate salts, succinate salts, and oxalate salts. The invention also relates to pharmaceutical compositions including a pharmaceutically effective amount of one or more salts of ?-GPA, as well as methods of treating cancer including administration of a formulation including a ?-GPA salt of the invention to a subject in need thereof.Type: ApplicationFiled: November 6, 2019Publication date: May 7, 2020Inventors: Eduardo J. MARTINEZ, Andreas G. GRILL, Aniruddh SINGH, Padmini KAVURU
-
Publication number: 20200010416Abstract: The present disclosure is directed to novel forms of apremilast and pharmaceutical compositions comprising any of the novel forms of apremilast. Also provided are processes for the preparation of novel forms of apremilast.Type: ApplicationFiled: August 29, 2019Publication date: January 9, 2020Applicant: Johnson Matthey Public Limited CompanyInventor: Padmini KAVURU
-
Patent number: 10512623Abstract: The present invention relates to new pharmaceutical salts of ?-GPA which exhibit improved physical properties. In particular, the invention relates to salts of ?-GPA with improved flow properties (e.g., improved Carr's index and/or Hausner ratio) such as fumarate salts, succinate salts, and oxalate salts. The invention also relates to pharmaceutical compositions including a pharmaceutically effective amount of one or more salts of ?-GPA, as well as methods of treating cancer including administration of a formulation including a ?-GPA salt of the invention to a subject in need thereof.Type: GrantFiled: October 27, 2017Date of Patent: December 24, 2019Assignee: Rgenix, Inc.Inventors: Eduardo J. Martinez, Andreas G. Grill, Aniruddh Singh, Padmini Kavuru
-
Publication number: 20190275056Abstract: Co-crystals comprising at least one nutraceutical compound and at least one co-crystal former with or without impurities. These co-crystals may be included in compositions (optionally also including other components such as pharmaceutically acceptable excipients, other nutritional supplements, etc.) having utility as pharmaceuticals, nutraceuticals, nutritional supplements, and foodstuffs.Type: ApplicationFiled: May 24, 2019Publication date: September 12, 2019Inventors: Michael John ZAWOROTKO, Heather CLARKE, Arora KAPILDEV, Padmini KAVURU, Roland Douglas SHYTLE, Twarita PUJARI, Lissette MARSHALL, Tien Teng ONG
-
Patent number: 10376521Abstract: Co-crystals comprising at least one nutraceutical compound and at least one co-crystal former with or without impurities. These co-crystals may be included in compositions (optionally also including other components such as pharmaceutically acceptable excipients, other nutritional supplements, etc.) having utility as pharmaceuticals, nutraceuticals, nutritional supplements, and foodstuffs.Type: GrantFiled: November 5, 2014Date of Patent: August 13, 2019Assignee: University of South FloridaInventors: Michael John Zaworotko, Heather Clarke, Arora Kapildev, Padmini Kavuru, Roland Douglas Shytle, Twarita Pujari, Lissette Marshall, Tien Teng Ong
-
Publication number: 20190106389Abstract: The present disclosure is directed to novel forms of apremilast and pharmaceutical compositions comprising any of the novel forms of apremilast. Also provided are processes for the preparation of novel forms of apremilast.Type: ApplicationFiled: December 6, 2018Publication date: April 11, 2019Applicant: Johnson Matthey Public Limited CompanyInventor: Padmini KAVURU
-
Patent number: 10196355Abstract: The present disclosure is directed to novel forms of apremilast and pharmaceutical compositions comprising any of the novel forms of apremilast. Also provided are processes for the preparation of novel forms of apremilast.Type: GrantFiled: June 20, 2016Date of Patent: February 5, 2019Assignee: Johnson Matthey Public Limited CompanyInventor: Padmini Kavuru
-
Patent number: 10130708Abstract: 2:1 cocrystals of amino acids and Li+ salts crystallize from hot water to afford water stable cationic networks based upon tetrahedral lithium cations: bilayered square grids, a lithium zeolitic metal-organic material (LiZMOM) and several lithium diamondoid metal-organic materials (LiDMOMs). The compositions may be used as a pharmaceutical for the treatment of suicidality and other disorders that require lithium to penetrate the blood brain barrier and exert therapeutic effects in the CNS. Advantageously, the novel cocrystal forms described herein may be used to lower the oral dose required to achieve therapeutic concentrations of lithium in the brain, thus reducing the peripheral toxicity and potentially broadening the therapeutic index in comparison to conventional lithium forms.Type: GrantFiled: March 26, 2012Date of Patent: November 20, 2018Assignee: University of South FloridaInventors: Michael John Zaworotko, Roland D. Shytle, Tien Teng Ong, Ryan N. Cantwell, Tranhha Nguyen, Adam John Smith, Padmini Kavuru
-
Publication number: 20180243248Abstract: The present invention relates to new pharmaceutical salts of ?-GPA which exhibit improved physical properties. In particular, the invention relates to salts of ?-GPA with improved flow properties (e.g., improved Carr's index and/or Hausner ratio) such as fumarate salts, succinate salts, and oxalate salts. The invention also relates to pharmaceutical compositions including a pharmaceutically effective amount of one or more salts of ?-GPA, as well as methods of treating cancer including administration of a formulation including a ?-GPA salt of the invention to a subject in need thereof.Type: ApplicationFiled: October 27, 2017Publication date: August 30, 2018Inventors: Eduardo J. MARTINEZ, Andreas G. GRILL, Aniruddh SINGH, Padmini KAVURU
-
Patent number: 9884813Abstract: The present invention relates to new pharmaceutical salts of ?-GPA which exhibit improved physical properties. In particular, the invention relates to salts of ?-GPA with improved flow properties (e.g., improved Carr's index and/or Hausner ratio) such as fumarate salts, succinate salts, and oxalate salts. The invention also relates to pharmaceutical compositions including a pharmaceutically effective amount of one or more salts of ?-GPA, as well as methods of treating cancer including administration of a formulation including a ?-GPA salt of the invention to a subject in need thereof.Type: GrantFiled: March 3, 2017Date of Patent: February 6, 2018Assignee: Rgenix, Inc.Inventors: Eduardo J. Martinez, Andreas G. Grill, Aniruddh Singh, Padmini Kavuru, Nicholas D. Paschalides, Stephen A. Wald
-
Publication number: 20170362175Abstract: The present disclosure is directed to novel forms of apremilast and pharmaceutical compositions comprising any of the novel forms of apremilast. Also provided are processes for the preparation of novel forms of apremilast.Type: ApplicationFiled: June 20, 2016Publication date: December 21, 2017Applicant: Johnson Matthey Public Limited CompanyInventor: Padmini KAVURU
-
Patent number: 9827217Abstract: The present invention relates to new pharmaceutical salts of ?-GPA which exhibit improved physical properties. In particular, the invention relates to salts of ?-GPA with improved flow properties (e.g., improved Carr's index and/or Hausner ratio) such as fumarate salts, succinate salts, and oxalate salts. The invention also relates to pharmaceutical compositions including a pharmaceutically effective amount of one or more salts of ?-GPA, as well as methods of treating cancer including administration of a formulation including a ?-GPA salt of the invention to a subject in need thereof.Type: GrantFiled: September 30, 2016Date of Patent: November 28, 2017Assignee: Rgenix, Inc.Inventors: Eduardo J. Martinez, Andreas G. Grill, Aniruddh Singh, Padmini Kavuru